A comprehensive view of Approved Drugs / Devices. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.
Recent Articles
sample of recent headlines, press releases and get more..
Hipra's Bimervax COVID-19 vaccine set to enter EU market; vaccine is cheaper and easier to distribute than Pfizer, touts fewer side effects, has longer-lasting effectiveness, and compatibility with lower distribution temperatures
Published:
March 31, 2023
by CE Noticias Financieras (Latin America)
|
FDA approves Abbott's Epic Max stented tissue valve for aortic regurgitation or stenosis treatment; the device offers improved blood flow and a low-profile frame for potential future interventions
Published:
March 31, 2023
by ENP Newswire
|
FDA approves Narcan nasal spray for OTC use to combat opioid overdoses; over 100,000 reported fatal overdoses driven by synthetic opioids prompt nonprescription access to life-saving medication.
Published:
March 30, 2023
by U.S. Food and Drug Administration (FDA)
|
Bristol Myers Squibb receives European Commission approval of Sotyktu deucravacitinib oral treatment for adults with moderate-to-severe plaque psoriasis; psoriasis affects about 14 million people in Europe, with 25% having moderate-to-severe cases
Published:
March 28, 2023
by Bristol-Myers Squibb Co.
|
FDA approves Regeneron’s Evkeeza evinacumab-dgnb as an adjunct to other lipid-lowering therapies for children aged 5 to 11 with homozygous familial hypercholesterolemia; HoFH is an ultra-rare inherited condition that affects about 1,300 people in the US
Published:
March 22, 2023
by Regeneron Pharmaceuticals Inc.
|
Ask us about our Government & Public Policy market view
Trending Chart
Interactive chart with headline count